ProfileGDS5678 / 1425780_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 97% 96% 96% 97% 96% 95% 96% 96% 96% 96% 96% 96% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.9916396
GSM967853U87-EV human glioblastoma xenograft - Control 29.1614997
GSM967854U87-EV human glioblastoma xenograft - Control 39.1235496
GSM967855U87-EV human glioblastoma xenograft - Control 49.0301896
GSM967856U87-EV human glioblastoma xenograft - Control 59.3311897
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.4738996
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3000995
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.8897796
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.9827696
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.8902696
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.7085396
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.0354296
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.8643996
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0938397